MBVX - MabVax Therapeutics Holdings, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.37
0.00 (0.00%)
As of 2:08PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.37
Open0.00
Bid0.76 x 100
Ask0.78 x 10200
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume45,512
Market Cap3.424M
Beta (3Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)-8.56
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • MabVax Therapeutics Audited Financial Statements Reinstated
    PR Newswire3 days ago

    MabVax Therapeutics Audited Financial Statements Reinstated

    SAN DIEGO, Oct. 16, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs, announces today that the Company's audited financial statements for 2017 and 2016 have been re-instated and brought current in quarterly filings with the Securities and Exchange Commission (the "SEC").  The re-instatement of audited financial statements was made possible through the combined efforts of the Company working with its prior auditors to bring current their procedures through last Friday, a requirement necessary to reinstate the audited financial statements. What made the re-instatement possible is that the Court of Chancery of the State of Delaware (the "Court")  on September 20, 2018, granted the Company's Verified Petition for Relief Under 8 Del. C. § 205, captioned In re: MabVax Therapeutics Holdings, Inc., C.A. No. 2018-0549-TMR (the "Delaware Petition"), as submitted, and entered an order validating (i) conversions of the Company's preferred stock into common stock that occurred between June 30, 2014 and February 12, 2018 and (ii) corporate acts that occurred during the same time period that we believed were approved by our stockholders but that, for reasons described in the Delaware Petition, may not have been approved by the requisite percentage of stockholder voting power during the same time period.

  • Delaware Court of Chancery Grants Petition Filed by MabVax Therapeutics
    PR Newswire28 days ago

    Delaware Court of Chancery Grants Petition Filed by MabVax Therapeutics

    SAN DIEGO , Sept. 21, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development ...

  • MabVax Therapeutics Files Suit Against Sichenzia Ross Ference LLP, a Law Firm that Formerly Represented the Company in Certain Corporate, Securities, and Securities and Exchange Commission Matters
    PR Newswirelast month

    MabVax Therapeutics Files Suit Against Sichenzia Ross Ference LLP, a Law Firm that Formerly Represented the Company in Certain Corporate, Securities, and Securities and Exchange Commission Matters

    SAN DIEGO , Sept. 11, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development ...

  • MabVax Therapeutics Engages New Independent Auditor
    PR Newswire2 months ago

    MabVax Therapeutics Engages New Independent Auditor

    Haskell & White LLP is a middle-market focused, full-service accounting firm located in Southern California with 30 years of practice concentrating on delivering audit and tax solutions, while also helping businesses with their strategic and succession planning, internal control gap identification and remediation, human capital needs and financial benchmarking studies.  The Orange County Business Journal has recognized Haskell & White among the "Best Places to Work" program for six consecutive years, and in 2017 the firm was recognized by Accounting Today, as a "Best Firm to Work For". MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer.

  • MabVax Therapeutics Announces Auditor Resignation
    PR Newswire2 months ago

    MabVax Therapeutics Announces Auditor Resignation

    SAN DIEGO , Aug. 8, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development ...

  • Business Wire2 months ago

    Robbins Arroyo LLP: MabVax Therapeutics Holdings, Inc. (MBVX) Misled Shareholders According to a Recently Filed Class Action

    Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of MabVax Therapeutics Holdings, Inc. (Other OTC: MBVX) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between June 30, 2014 and May 18, 2018. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

  • Business Wire3 months ago

    Glancy Prongay & Murray LLP Files a Securities Class Action on Behalf of MabVax Therapeutics Holdings Investors (MBVX); Expands Existing Class Period

    National law firm Glancy Prongay & Murray LLP (“GPM”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California on behalf of persons and/or entities that purchased or otherwise acquired the securities of MabVax Therapeutics Holdings Investors (“MabVax”) (MBVX) between June 30, 2014 and May 18, 2018, inclusive (the “Expanded Class Period”). Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934. MabVax investors are hereby notified that they have until August 3, 2018 to move the Court to serve as lead plaintiff in this action.

  • Delaware Court of Chancery Sets Hearing Date On Petition Filed By MabVax Therapeutics
    PR Newswire3 months ago

    Delaware Court of Chancery Sets Hearing Date On Petition Filed By MabVax Therapeutics

    SAN DIEGO, Aug. 3, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announces today that the Court of Chancery of the State of Delaware (the "Court") has set September 20, 2018, at 2:00 PM ET (the "Hearing Date") as the date and time of the hearing (the "Hearing") on the Verified Petition for Relief Under 8 Del. C. § 205, captioned In re: MabVax Therapeutics Holdings, Inc., C.A. No. 2018-0549-TMR (the "Delaware Petition"). The Hearing will be held at the Leonard L. Williams Justice Center, Court of Chancery, 500 North King Street, Wilmington, Delaware.

  • ACCESSWIRE3 months ago

    DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MabVax Therapeutics Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / August 2, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MabVax Therapeutics Holdings, Inc. (''MabVax'' or ''the Company'') (OTC PINK: MBVX). If you purchased or otherwise acquired MabVax shares, and would like more information about the investigation, we encourage you to contact Brian Schall, or Sherin Mahdavian, of The Schall Law firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights without cost to you.

  • GlobeNewswire3 months ago

    DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against MabVax Therapeutics Holdings (MBVX) & Lead Plaintiff Deadline – August 3, 2018

    This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/mbvx or you may contact Peretz Bronstein, Esq.

  • MabVax Therapeutics Announces Board of Director Changes
    PR Newswire3 months ago

    MabVax Therapeutics Announces Board of Director Changes

    SAN DIEGO, Aug. 1, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today that four members of the Company's Board of Directors have resigned from their positions effective as of July 31, 2018.  There were no disagreements between the Board members and management. The Company has been evaluating several strategic options intended on enhancing stockholder value, and is currently in active discussions with several companies about possible business options. In a separate action, Gregory Hanson CMA, MBA, the Chief Financial Officer of the Company since July 2014, and of its subsidiary, MabVax Therapeutics, Inc., since February 2014, has been appointed to fill one of the vacant board seats.  Mr. Hanson has over 30 years' experience serving as the CFO, financial executive and board member of public and private life sciences and hi-tech companies.

  • GlobeNewswire3 months ago

    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against MabVax, Farmland, and ACADIA, and Encourages Investors to Contact the Firm

    NEW YORK, Aug. 01, 2018-- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of MabVax Therapeutics Holdings, Inc., Farmland Partners ...

  • ACCESSWIRE3 months ago

    3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MabVax Therapeutics Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / July 31, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MabVax Therapeutics Holdings, Inc. (''MabVax'' or ''the Company'') (OTC PINK: MBVX). If you purchased or otherwise acquired MabVax shares, and would like more information about the investigation, we encourage you to contact Brian Schall, or Sherin Mahdavian, of The Schall Law firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights without cost to you.

  • GlobeNewswire3 months ago

    MBVX ALERT NOTICE: Rosen Law Firm Reminds MabVax Therapeutics Holdings, Inc. Investors of Important August 3 Deadline in Class Action – MBVX

    NEW YORK, July 31, 2018-- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MabVax Therapeutics Holdings, Inc. between March 14, 2016 and May 18, 2018, both dates ...

  • GlobeNewswire3 months ago

    The Law Offices of Howard G. Smith Reminds Investors of August 3rd Deadline in the Class Action Lawsuit Against MabVax Therapeutics Holdings Inc. (MBVX)

    Law Offices of Howard G. Smith reminds investors of the August 3, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased MabVax Therapeutics Holdings Inc. (“MabVax” or the “Company”) (OTC: MBVX) securities between March 14, 2016 and May 18, 2018, inclusive (the “Class Period”). Investors suffering losses on their MabVax investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com. The complaint filed in this class action alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.

  • MabVax Therapeutics Files Delaware Petition
    PR Newswire3 months ago

    MabVax Therapeutics Files Delaware Petition

    SAN DIEGO , July 27, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTC: MBVX), a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the development ...

  • GlobeNewswire3 months ago

    FINAL DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX) To Contact The Firm

    The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of MabVax Therapeutics Holdings, Inc. (MBVX) (“MabVax” or the “Company”) securities during the period between March 14, 2016 and May 18, 2018, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until August 3, 2018 to seek appointment as lead plaintiff. If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in MabVax securities during the Class Period.  Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.

  • ACCESSWIRE3 months ago

    IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MabVax Therapeutics Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / July 24, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MabVax Therapeutics Holdings, Inc. (''MabVax'' or ''the Company'') (MBVX). If you purchased or otherwise acquired MabVax shares, and would like more information about the investigation, we encourage you to contact Brian Schall, or Sherin Mahdavian, of The Schall Law firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights without cost to you.

  • Business Wire3 months ago

    August 3rd Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against MabVax Therapeutics Holdings Inc. (MBVX)

    National securities litigation law firm Glancy Prongay & Murray LLP (“GPM”) reminds investors of the August 3, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased MabVax Therapeutics Holdings Inc. (“MabVax” or the “Company”) (NASDAQ: MBVX) securities between March 14, 2016 and May 18, 2018, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. Investors suffering losses on their MabVax investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to shareholders@glancylaw.com.

  • MBVX EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against MabVax Therapeutics Holdings, Inc.; Upcoming Deadline - MBVX
    PR Newswire3 months ago

    MBVX EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against MabVax Therapeutics Holdings, Inc.; Upcoming Deadline - MBVX

    NEW YORK , July 19, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of MabVax Therapeutics ...

  • Business Wire3 months ago

    The Law Offices of Howard G. Smith Reminds Investors of August 3rd Deadline in the Class Action Lawsuit Against MabVax Therapeutics Holdings Inc. (MBVX)

    Law Offices of Howard G. Smith reminds investors of the August 3, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased MabVax Therapeutics Holdings Inc. (“MabVax” or the “Company”) (NASDAQ: MBVX) securities between March 14, 2016 and May 18, 2018, inclusive (the “Class Period”). Investors suffering losses on their MabVax investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

  • ACCESSWIRE3 months ago

    ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against MabVax Therapeutics Holdings, Inc. – MBVX

    NEW YORK, NY / ACCESSWIRE / July 15, 2018 / Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of MabVax Therapeutics Holdings, Inc. (NASDAQ: ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: MabVax Therapeutics and CEL-SCI

    NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Shares of MabVax as well as Cel-SCI Corporation were on a gaining frenzy in Monday's trading session as each company presented positive developments. MabVax shares rose on the news that the company has signed an asset acquisition and related agreements with Boehringer Ingelheim. Shares of CEL-SCI Corporation were heading higher after the company issued a positive shareholder letter.

  • MabVax Therapeutics and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers
    PR Newswire3 months ago

    MabVax Therapeutics and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers

    SAN DIEGO, July 9, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (MBVX), a clinical-stage oncology drug development company and Boehringer Ingelheim today announced they have signed an asset acquisition and related agreements centered on MabVax's program targeting a glycan commonly overexpressed on multiple solid tumor cancers. Boehringer Ingelheim has acquired all rights in and to the program. MabVax will receive a total of US $11 million in upfront and near-term milestones as well as downstream regulatory milestone payments plus further earn-out payments.  The asset acquisition is separate and distinct from other programs under development at MabVax, enabling MabVax to retain all rights to its lead HuMab-5B1antibody program which is in Phase 1 clinical trials as a therapeutic product and as a diagnostic product, as well as other antibody discovery programs from the Company's rich antibody discovery portfolio targeting other cancer antigens.